Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

APLNR promotes the progression of osteosarcoma by stimulating cell proliferation and invasion

Cui, Leia,,*; Zhang, Jing-Yuanb,,*; Ren, Zhi-Pengd; Zhao, He-June; Li, Gui-Shic

doi: 10.1097/CAD.0000000000000785
Preclinical Reports

Osteosarcoma is the most common type of bone malignancies with a poor prognosis. In recent years, targeted therapy has shown great potential in the treatment of osteosarcoma, and more effective therapeutic targets for this disease need to be developed. APLNR is a seven transmembrane G-protein-coupled receptor expressed widely in multiple tissues. As has been reported, APLNR is involved in various physiological and pathological processes. Although APLNR plays a role in the development and progression of multiple tumors, the potential role of APLNR in osteosarcoma, a highly malignant tumor, remains unclear. Here, we reported that APLNR expression was correlated positively with clinical features including tumor size and stage of osteosarcoma. We found that APLNR knockdown inhibited the proliferation and invasion of osteosarcoma cells in vitro. In addition, APLNR could promote the progression and metastasis of osteosarcoma in mice. Collectively, this study showed the potential link between APLNR and osteosarcoma and suggested APLNR as a novel therapeutic target for osteosarcoma.

Departments of aOphthalmology Surgery


cJoint Orthopaedics, Yantai Yuhuangding Hospital, Yantai, Shandong Province

dDepartment of Orthopedics, Tianjin Hospital

eDepartment of Endocrinology, Tianjin First Center Hospital, Tianjin, China

* Lei Cui and Jing-Yuan Zhang contributed equally to the writing of this article.

Received 8 November 2018 Revised form accepted 3 March 2019

Correspondence to Gui-Shi Li, MSc, Department of Joint Orthopaedics, Yantai Yuhuangding Hospital, No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong Province 264000, ChinaTel/fax: + 86 053 566 91999; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.